» Articles » PMID: 22851857

Cellular and Molecular Mechanisms of Intestinal Fibrosis

Overview
Specialty Gastroenterology
Date 2012 Aug 2
PMID 22851857
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrosis is a chronic and progressive process characterized by an excessive accumulation of extracellular matrix (ECM) leading to stiffening and/or scarring of the involved tissue. Intestinal fibrosis may develop in several different enteropathies, including inflammatory bowel disease. It develops through complex cell, extracellular matrix, cytokine and growth factor interactions. Distinct cell types are involved in intestinal fibrosis, such as resident mesenchymal cells (fibroblasts, myofibroblasts and smooth muscle cells) but also ECM-producing cells derived from epithelial and endothelial cells (through a process termed epithelial- and endothelial-mesenchymal transition), stellate cells, pericytes, local or bone marrow-derived stem cells. The most important soluble factors that regulate the activation of these cells include cytokines, chemokines, growth factors, components of the renin-angiotensin system, angiogenic factors, peroxisome proliferator-activated receptors, mammalian target of rapamycin, and products of oxidative stress. It soon becomes clear that although inflammation is responsible for triggering the onset of the fibrotic process, it only plays a minor role in the progression of this condition, as fibrosis may advance in a self-perpetuating fashion. Definition of the cellular and molecular mechanisms involved in intestinal fibrosis may provide the key to developing new therapeutic approaches.

Citing Articles

Bright Luminal Sign on High b-Value Diffusion-Weighted Magnetic Resonance Enterography Imaging as a New Biomarker to Predict Fibrotic Strictures in Crohn's Disease Patients: A Retrospective Preliminary Study.

Stoppino L, Piscone S, Quarta Colosso O, Saccone S, Milillo P, Della Valle N J Imaging. 2024; 10(11).

PMID: 39590747 PMC: 11595469. DOI: 10.3390/jimaging10110283.


Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.

Touny A, Venkataraman B, Ojha S, Pessia M, Subramanian V, Hariharagowdru S Nutrients. 2024; 16(21).

PMID: 39519465 PMC: 11547603. DOI: 10.3390/nu16213633.


Identification of TIMP1-induced dysregulation of epithelial-mesenchymal transition as a key pathway in inflammatory bowel disease and small intestinal neuroendocrine tumors shared pathogenesis.

Tran M Front Genet. 2024; 15:1376123.

PMID: 39233736 PMC: 11371700. DOI: 10.3389/fgene.2024.1376123.


Pharmacological Inhibition of N-Acylethanolamine Acid Amidase (NAAA) Mitigates Intestinal Fibrosis Through Modulation of Macrophage Activity.

Nani M, Pagano E, De Cicco P, Lucariello G, Cattaneo F, Tropeano F J Crohns Colitis. 2024; 19(2).

PMID: 39211986 PMC: 11836880. DOI: 10.1093/ecco-jcc/jjae132.


Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center.

Zeng Y, Li J, Zheng Y, Zhang D, Zhong N, Zuo X Ann Med. 2024; 56(1):2391536.

PMID: 39149760 PMC: 11328799. DOI: 10.1080/07853890.2024.2391536.


References
1.
Meijer M, Mieremet-Ooms M, van Hogezand R, Lamers C, Hommes D, Verspaget H . Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007; 13(21):2960-6. PMC: 4171149. DOI: 10.3748/wjg.v13.i21.2960. View

2.
Pender S, Tickle S, Docherty A, Howie D, Wathen N, MacDonald T . A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997; 158(4):1582-90. View

3.
Serrano-Mollar A, Closa D, Prats N, Blesa S, Martinez-Losa M, Cortijo J . In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol. 2003; 138(6):1037-48. PMC: 1573750. DOI: 10.1038/sj.bjp.0705138. View

4.
Rieder F, Fiocchi C . Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009; 6(4):228-35. DOI: 10.1038/nrgastro.2009.31. View

5.
Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Chrousos G, Anagnou N . NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease. World J Gastroenterol. 2010; 16(14):1753-8. PMC: 2852824. DOI: 10.3748/wjg.v16.i14.1753. View